Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Phase 3
18+
2 sites in NV, OH
About this study
This Phase 3 study is testing gemcitabine in people with pancreatic adenocarcinoma. The primary outcome being measured is Overall survival (OS).
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
gemcitabine, paclitaxel (Taxane chemotherapy; stabilizes microtubules)
injection (Injection), infusion
Primary: Overall survival (OS), Progression free survival (PFS)
Secondary: Duration of response (DOR), Health-related outcome assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Pancreatic Cancer Module (EORTC QLQ-PAN26), Incidence of adverse events (AEs), Objective response rate (ORR), Quality of life as assessed with European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Oncology